Immunic, INC Form 4 insider transactions

Andreas Muehler, Chief Medical Officer of Immunic, Inc., reports the repricing of stock options following stockholder approval.

Glenn Whaley, CFO of Immunic, Inc., reports changes in beneficial ownership due to the repricing of employee stock options.

Director Joerg Neermann reports adjustments to stock options following stockholder approval to reduce the exercise price of eligible options to $1.72 per share.

Director Monika Maria Toernsen reports repricing of stock options at Immunic, Inc. following stockholder approval.

Immunic's CEO, Daniel Vitt, purchased 14,000 shares of the company's common stock at $1.3095 per share on February 26, 2024.